Resmed Inc (NYSE:RMD) reported better-than-expected earnings for the second quarter on Thursday.

The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus estimate of $1.321 billion.

“Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,” said Resmed’s Chairman and CEO, Mick Farrell.

ResMed shares rose 2.1% to trade at $277.70 on Friday.

These analysts made changes to their …

Full story available on Benzinga.com